THE biotech sector is tipped to prove more rewarding this year than the “zero-sum game” of last year when big share price drops cancelled out hefty gains in some companies. Analysts linked the rosier outlook to factors such as companies creating products (including everything from anti-cancer drugs to medical devices), developing wider product pipelines and nearing key milestones. Investor interest might also revive in the sector after a focus on mining and resources last year.
